Telecon Advice, January 8, 2010 - Menveo

Submission ID: **Office: OVRR**
BLA 125300 Menveo
Title: *Meningococcal (Neisseria meningitidis) Tetravalent Oligosccharide Serogroups A, C, Y, W-135 Conjugate (diphtheria toxin CRM197; Corynebacterium diphtheriae) Vaccine*
Sponsor: *Novartis Vaccines and Diagnostics Inc*
Telecon Date/Time: *8-JAN-2010 12:08 PM*
Telephone Number: *(617) 871-4280*
Author: *CARA FIORE*
Purpose: *ADVICE (AD)*
FDA Participants:
CARA R FIORE
Sponsor Participants:
CHRIS WEBSTER
Amendments: *None*
References

1. Fax 17NOV09 – see EDR
2. Telecon 20NOV09 - see EDR
3. Fax 01DEC09 - see EDR

Summary of Discussion:
This telecon conveyed comments on the newest carton container submission (submitted 15DEC09, A018). Novartis responded to all of CBER's previous comments conveyed on 20NOV09, but the font on the MenCYW-135 drug product vial is not according to the CFR. It appears that "MENVEO" is a wider font than "MenCYW-135" that is located on the vertical axis of the label vial. After magnifying this on the screen, this is definitely the case.
Comments conveyed to sponsor:

1. Please use the identical size font (or smaller) on the vial for the MenCYW-135 drug product as the typing in "MENVEO" on the vertical axis of the label.

MenACWY Conjugate Vaccine lot number :	**----------**	**Reason for submission**
		[ ] For release
Manufacturer name:	Novartis Vaccines and Diagnostics Srl	[ ] For surveillance
		[ ] For licensing action
Manufacturer address:	Bellaria - Rosia, 53018 Sovicille	STN:
	--b(4)---(Italy)	[ ] Corrected protocol

MenACWY Conjugate Vaccine lot number :	----------	**Reason for submission**
Trade name	MENVEO	
US License No.	----------	
Date of packaging	----------	
Type of packing container	Box (*presentation*)	
No. of packing containers	----------	
No. of doses per final container	----------	
Volume of single human dose, after reconstitution	0.5 mL	
of Men A lyophilized conjugate component powder		
with Men CWY liquid conjugate component		
Prescribed composition for human dose	Men A oligosaccharide	10 mcg
	Men C oligosaccharide	5 mcg
	Men W oligosaccharide	5 mcg
	Men Y oligosaccharide	5 mcg
Expiry date	----------	
Date of start period of validity	----------	
Storage conditions of packed product	2 - 8° C, protected from light. Do not freeze	

All tests on this lot are reported and pass specifications as required.

_____ _____

Dr. Stefano Viti
Quality Assurance / Qualified Person

Date

Summary

Summary		
- Packaging Plan		---
- Meningococcal ACWY Conjugate Vaccine	Lot ----------	---
- Men A Lyophilized Conjugate Component	Lot ----------	---
- Men CWY Liquid Conjugate Component	Lot ----------	---

---

1 Page determined to be not releasable:
b(4)

Tests on packing lot

Identity test for Meningococcal C conjugate vaccine (Specification: ---b(4)----)
Method ---b(4)---
Date of test August 17, 2009
Result ---b(4)---

Identity test for Meningococcal AWY conjugate vaccine (Specification: Positive)
Method ---b(4)---
Date of test August 13, 2009
Result ---b(4)---

Test	Method	Specifications	Date of Test	Results
Identity for MenC Conjugate Vaccine	---b(4)---	---b(4)---		
Identity for MenAWY Conjugate Vaccine	---b(4)---	---b(4)---		

MENINGOCOCCAL GROUP A CONJUGATE COMPONENT LOT ----------

Name and address of manufacturer: Novartis Vaccines and Diagnostics ---b(4)---
Final lot: ----------
Type of container: Vial
No. of final containers (after inspection): ----------
No. of doses per final container: One
Volume of single human dose, after reconstitution of Men A lyophilized conjugate component powder with Men CWY liquid conjugate component: 0.5 mL
Date of start period of validity: ----------
Expiry date: ----------
Storage conditions of final product: 2 - 8° C, protected from light. Do not freeze
Result: --b(4)---
Result: ---------- mcg/mL
[b(4)]

---

16 Pages determined to be not releasable:
b(4)

MEN A FINAL BULK LOT ----------
Information on blending
Name and address of manufacturer: Novartis Vaccines and Diagnostics ----b(4)-----
Date of manufacturing: ----------
Men A - CRM conjugate component
Conjugate concentrated bulk lot: ----------
Concentration: ---------- mg/mL
Volume: ---------- mL

---b(4)----------
--b(4)------: --b(4)------
--b(4)--------: ---------- mL
--b(4)------: --b(4)------
--b(4)------: ---------- mL
--b(4)------: ----------
--b(4)------: ----------
--b(4)------: ---------- mL
--b(4)------: --b(4)------
Tests on final bulk
Sterility test (Specification: Sterile)
Method: --b(4)------.
Media: FTM and SCDM
Volume tested: ---------- mL

Date of test: Record date beginning - date end
Result: ----------

MEN A LYOPHILIZED COMPONENT LOT ----------
Production details of final lot
Name and address of manufacturer: Novartis Vaccines and Diagnostics --b(4)------ KG
Lot of final bulk used in manufacture: ----------
Date of filling: ----------
Filled volume: ---------- mL
Date of freeze-drying: Record date beginning - date end
Storage conditions of final product: 2 - 8° C, protected from light. Do not freeze

---

Tests on final lot (*)
Identity test for MenA - CRM (Specification: --b(4)------)
Method: --b(4)------
Date of test: ----------
Result: ----------
Residual moisture (Specification--b(4)------
Method: --b(4)------
Date of test: ----------
Result: ---------- %
Protein content (Specification: --b(4)------
Method: --b(4)------
Date of test: ----------
Result: ---------- mcg/vial

(*) - *Tests were performed at Novartis Vaccines and Diagnostics ---b(4)--- - Italy*

Appearance of lyophilised plug (Specification: --b(4)------)
Method: Visual examination
Date of test: ----------
Result: ----------

Appearance after reconstitution with WFI (Specification: --b(4)------) (*)
Method: Visual examination
Date of test: ----------

Result: ----------

b(4) (Specification: --b(4)------
Method: --b(4)------
Date of test: ----------
Result: ----------
--b(4)------ content, -------b(4)----------
Method: --b(4)------
Date of test: ----------
Result: ---------- mcg/vial

--b(4)------content, ----------b(4)----------
Method:--b(4)------
Date of test: ----------
Result: ---------- %

--b(4)------ content (Specification: --b(4)------
Method: --b(4)------
Date of test: ----------
Result: ---------- mg/vial

Endotoxin content (Specification: --b(4)------
Method: -------b(4)----------
Date of test: ----------
Result: ---------- IU/vial
(*) *Reconstituted with Water for Injections.*

Sterility test (Specification: Sterile)
Method: ---b(4)-----
Media used: FTM and SCDM
No. of containers tested: ----------
Date of test: Record date beginning - date end
Result: ----------

General safety (Specification: Non toxic) (*)		
Method	---b(4)-----.	---b(4)-----.
No. and type of animals injected	b(4) mice	2 guinea pigs
Weight of animals	b(4) – 22 g/animal	--b(4)-- g/animal
Route of injection	Intraperitoneally	Intraperitoneally
Volume of injection	0.5 mL	5.0 mL

General safety (Specification: Non toxic) (*)		
Date of injection	----------	----------
Period of observation	Date beginning - date end	Date beginning - date end
Result	----------	----------

(*) *Reconstituted with a lot of MenCWY liquid (i.e. tetravalent combination)*

---

32 Pages determined to be not releasable:
b(4)

Test on final bulk
Sterility test (Specification: Sterile)
Method: ---b(4)----------
Media: FTM and SCDM
Volume tested: ---------- mL
Date of test: Record date beginning - date end
Result: ----------

FINAL LOT ----------
Production details of final lot (*)
Name and address of manufacturer: Novartis Vaccines and Diagnostics Srl, Bellaria - Rosia, 53018 Sovicille ---b(4)---(Italy)
Lot of final bulk used in manufacture: ----------
Date of filling: ----------
Filled volume: ---------- mL
Type of container: Vial
No. of final containers (after inspection): ----------
Storage conditions of final product: 2 - 8° C, protected from light. Do not freeze

Tests on final lot
Identity test for MenC - CRM (Specification: Positive)
Method: -b(4)---
Date of test: ----------

Result: ----------

Identity test for MenW – CRM and MenY – CRM (Specification: Positive)
Method: -b(4)---
Date of test: ----------
Result: ----------
Appearance (Specification: Colorless clear liquid)
Method: Visual examination
Date of test: ----------
Result: ----------
(*) - *Tests were performed at Novartis Vaccines and Diagnostics ---b(4)--- Italy*

---

b(4) (Specification: 6.7 - 7.7)
Method: -b(4)---
Date of test: ----------
Result: ----------
---b(4)------ (Specification: --b(4)----------)
Method: ---b(4)----------
Date of test: ----------
Result: ---------- --b(4)----
Extractable volume (Specification: -b(4)------)
Method: --b(4)---------
Date of test: ----------
Result: ---------- mL
Men C --b(4)------, as sialic acid (Specification: --b(4)----------)
Method: --b(4)---------
Date of test: ----------
Result: ---------- mcg/mL
Men C --b(4)---------- (Specification: -b(4)----
Method: -b(4)--------
Date of test: ----------
Result: ---------- %
Men W --b(4)----------(Specification: ---b(4)---------)
Method: --b(4)-------
Date of test: ----------
Result: ---------- mcg/mL
Men W ---------b(4)----------
Method: --b(4)----------
Date of test: ----------
Result: ---------- %

Men Y ----b(4)----------
Method: --b(4)---------
Date of test: ----------
Result: ---------- mcg/mL

Men Y -----b(4)----------
Method: --b(4)--------
Date of test: ----------
Result: ---------- %

Endotoxin content (Specification: --b(4)----------
Method: ---b(4)----------
Date of test: ----------
Result: ---------- IU/vial
Sterility test (Specification: Sterile)
Method: --b(4)----------.
Media used: FTM and SCDM
No. of containers tested: ----------
Date of test: Record date beginning - date end
Result: ----------

General safety (Specification: Non toxic)		
Method	--b(4)---------	--b(4)------
No. and type of animals injected	b(4) mice	2 guinea pigs
Weight of animals	-b(4)---animal	-b(4)-------/animal
Route of injection	Intraperitoneally	Intraperitoneally
Volume of injection	0.5 mL	5.0 mL
Date of injection	----------	----------
Period of observation	Date beginning - date end	Date beginning - date end
Result	----------	----------

(*) *MenA lyophilized reconstituted with MenCWY liquid (i.e. tetravalent combination)*